ESMO 2023 Highlights

CE / CME

Key Studies in Breast, Lung, Gastrointestinal, Genitourinary, and Skin Cancers: CCO Independent Conference Highlights of the 2023 ESMO Congress

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: December 22, 2023

Expiration: December 21, 2024

Natasha Leighl
Natasha Leighl, MD, MMSc, FRCPC, FASCO
Evan J. Lipson
Evan J. Lipson, MD
John Marshall
John Marshall, MD
Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD
Daniel P. Petrylak
Daniel P. Petrylak, MD

Activity

Progress
1 2
Course Completed

References

Lung and Thyroid Cancers

  • Alectinib [prescribing information]. South San Francisco, CA: Genentech; 2021.
  • Cascone T, Awad MM, Spicer JD, et al. CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA1.
  • Chen MF, Chaft JE. Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review. Transl Lung Cancer Res. 2023;12:337-345.
  • Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324-336.
  • Dowlati A, Cervantes A, Babu S, et al. Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): preliminary results from the phase II TROPiCS-03 basket trial. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract 1990MO.
  • Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023;41:385-394.
  • Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  • Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-673.
  • Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987-995.
  • Hadoux J, Elisei R, Brose MS, et al. Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023a. Abstract LBA3.
  • Hadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023b;389:1851-1861.
  • Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672-1684.
  • Johnson ML, Janne PA, Goto Y, et al. Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract 1319MO.
  • Lisberg A, Ahn MJ, Paz-Ares L, et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA12.
  • Locati L, Cavalieri S, Dal Maso L, et al. Rare thyroid malignancies in Europe: data from the information network on rare cancers in Europe (RARECAREnet). Oral Oncol. 2020;108:104766.
  • Loong HHF, Goto K, Solomon BJ, et al. Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA4.
  • National Comprehensive Cancer Network. Clinical practice guidelines in oncology: NSCLC. v.5.2023. nccn.org. Accessed December 1, 2023.
  • National Comprehensive Cancer Network. Clinical practice guidelines in oncology: thyroid carcinoma. v.4.2023. nccn.org. Accessed December 1, 2023.
  • Nivolumab [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2023.
  • Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  • Pembrolizumab [prescribing information]. Rahway, NJ: Merck; 2023.
  • Romei C, Casella F, Tacito A, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J Med Genet. 2016;53:729-734.
  • Selpercatinib [prescribing information]. Indianapolis, IN: Eli Lilly; 2022.
  • Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678-4687.
  • Solomon BJ, Ahn JS, Dziadziuszko R, et al. ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA2.
  • Spicer JD, Gao S, Liberman M, et al. Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA56.
  • Wakelee HA, Liberman M, Kato T, et al. KEYNOTE-671: randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023a. Abstract LBA100.
  • Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023b;389:491-503.
  • Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835.
  • Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;[Epub ahead of print]. 
  • Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023;389:1839-1850. 

Breast Cancer

  • Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2023.
  • Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med. 2020;144:545-563.
  • Alves CL, Ditzel JH. Drugging the PI3K/AKT/mTOR pathway in ER+ breast cancer. Int J Mol Sci. 2023;24:4522.
  • André F, Park YH, Kim S-B, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401:1773-1785.
  • Bardia A, Hortobagyi G, Lipatov O, et al. Invasive disease–free survival across key subgroups from the Phase III NATALEE study of ribociclib + a nonsteroidal aromatase inhibitor in patients with HR+/HER2−early breast cancer. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023a. Abstract LBA23.
  • Bardia A, Jhaveri K, Kalinsky K, et al. TROPION-Breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Future Oncol. 2023b;[Epub ahead of print].
  • Bardia A, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer: primary results from the randomised phase 3 TROPION-Breast01 trial. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023c. Abstract LBA11.
  • Cardoso F, McArthur H, Schmid P, et al. KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab or placebo + chemotherapy followed by adjuvant pembrolizumab or placebo + endocrine therapy for early-stage high-risk ER+/HER2–breast cancer. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA21.
  • Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143-1154.
  • D’Arienzo A, Verrazzo A, Pagliuca M, et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine. 2023;62:102113.
  • Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics, Inc.; 2023.
  • Goetz MP, Turner N, Sasano H, et al. Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 240MO.
  • Harbeck N, Rastogi P, O’Shaughnessy, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA17.
  • Hurvitz SA, Modi S, Li W, et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 377O.
  • Jhaveri KL, Jeselsohn R, Ma CX, et al. Imlunestrant, with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 383MO.
  • Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998. 
  • Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90.
  • Lin NU, Murthy RK, Abramson V, et al. tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 2023;9:197-205.
  • Loi S, Curigliano G, Salgado R, et al. A randomized, double-blind trial of nivolumab vs placebo with neoadjuvant chemotherapy followed by adjuvant endocrine therapy in patients with high-risk, ER+ HER2−primary breast cancer. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA20.
  • Meric-Bernstam F, Krop IE, Juric D, et al. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor–positive/HER2-negative breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD13-08.
  • Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610-621.
  • National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.4.2023. nccn.org. Accessed December 1, 2023.
  • O’Shaughnessy J, Cicin I, Testa L, et al. Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): analyses from the monarchE study. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract 274P.
  • Pembrolizumab [prescribing information]. North Wales, PA: Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co., Inc.; 2023.
  • Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124:13-26.
  • Rugo HS, Bianchini G, Cortes J, et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7:100553.
  • Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.
  • Schmid P, Cortes J, Dent R, et al. Pembrolizumab or placebo + chemotherapy followed by pembrolizumab or placebo for early-stage triple-negative breast cancer: updated event-free survival results from the phase 3 KEYNOTE-522 study. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA18.
  • Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  • Slamon DJ, Stroyakovskiy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA500.
  • Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 1003.

Gastrointestinal Cancers

  • Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948-1957. 
  • Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363-2376.
  • Chalabi M, Verschoor YL, van den Berg J, et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Presented at: European Society for Medical Oncology Congress 2022; September 9-13, 2022. Abstract LBA7.
  • Chan J, Faris J, Murphy J, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). Presented at: American Society of Clinical Oncology 2017 Gastrointestinal Cancers Symposium; January 19-21, 2017. Abstract 228.
  • Chan J, Geyer S, Ou FS, et al. Alliance A021602: phase III, double-blinded study of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression of prior therapy (CABINET). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA53.
  • Janjigian YY, Kawazoe A, Yañez P, et al. Combined PD-1 and HER2 blockade for HER2-positive gastric cancer. Nature. 2021;600:727-730.
  • Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, phase III MATTERHORN study. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023a. Abstract LBA73.
  • Janjigian Y, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023b. Abstract 1511O.
  • Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023c;[Epub ahead of print].
  • Lauricella E, Mandriani B, Cavallo F, et al. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications. Front Oncol. 2022;12:957068.
  • Lonardi S, Pietrantonio F, Tarazona Llavero N, et al. The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA28.
  • Pembrolizumab [prescribing information]. Rahway, NJ: Merck & Co. Inc.; 2023.
  • Taieb J, Pederson L, Sinicrope F, et al. Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of 7 trials. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023a. Abstract 553O.
  • Taieb J, Sinicrope F, Pederson L, et al. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. Ann Oncol. 2023b; 34:1025-1034.
  • US Food and Drug Administration. FDA amends pembrolizumab’s gastric cancer indication. fda.gov/drugs/resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication. Accessed December 4, 2023.
  • Verschoor Y, van den Berg J, Balduzzi S, et al. Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA53.

Genitourinary Cancers

  • Enfortumab-vedotin-ejfv. [prescribing information]. Bothell, WA: Seagen Inc.; 2023.
  • Galsky MD, Moshier E, Krege S, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119:3012-3019. 
  • Koshkin VS, Henderson N, James M, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022;128:1194-1205.
  • McGregor BA, Sonpavde GP, Kwak L, et al. The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023a. Abstract 2360O. 
  • McGregor BA, Sonpavde GP, Kwak L, et al. The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2023b;[Online ahead of print]. 
  • O’Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41:4107-4117. 
  • Powles TB, Valderrama BP, Gupta S, et al. EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA6. 
  • Sartor O, Castellano D, Herrmann K, et al. Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA13. 
  • van der Heijden MS, Sonpavde GP, Powles TB, et al. Nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023a. Abstract LBA7. 
  • van der Heijden MS, Sonpavde G, Powles T et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023b;389:1778-1789. 
  • Zschäbitz S, Biernath N, Hilser T, et al. Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort. Eur Urol Open Sci. 2023;53:31-37. 

Skin Cancers

  • Gross N, Miller DM, Khushalani NI, et al. A phase 2 study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): one-year follow-up. Presented at: European Society of Medical Oncology Congress 2023; October 20-24, 2023. Abstract 1088MO.
  • Lipson EJ, Dolfi S, Tang H, et al. Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO) + RELA or NIVO alone in RELATIVITY-047. Presented at: European Society of Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA51.
  • Long GV, Hodi FS, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. NEJM Evid. 2023;2(4).
  • Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34. 

Trastuzumab Deruxtecan Across Solid Tumors With HER2 Mutations 

  • Fam-trastuzumab deruxtecan-nxki [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; 2022.
  • Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852-4863. 
  • Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241-251. 
  • Li BT, Meric-Bernstam F, Bardia A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract 6540.
  • Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 2020;10:688-701.